Browsing Tag
Sanofi
75 posts
Regeneron earnings surge as Dupixent sales hit $6.5bn and Sanofi expands partnership
Regeneron revenue jumps 36% to $5.1 billion as Dupixent sales surge and Sanofi expands its partnership. Explore the earnings outlook.
Aclaris Therapeutics prices $50m share offering following positive ATI-052 trial results
Aclaris Therapeutics targets $50M financing after ATI-052 trial success. Explore its cash position, dilution risks and Phase 2b strategy.
EUROAPI targets North American compounding market through MEDISCA as peptide strategy expands
EUROAPI has entered a strategic distribution partnership with MEDISCA to expand European-manufactured pharmaceutical ingredient access in North America and explore peptide opportunities. The agreement offers a potential route to new customers as EUROAPI restructures its manufacturing business, but undisclosed contract economics and tightening US compounding regulations leave its financial impact uncertain.
Sanofi pays $1bn upfront in Regeneron alliance worth up to $8bn
Sanofi and Regeneron Pharmaceuticals have reset their two-decade immunology alliance with four long-acting antibody programmes, a $1 billion upfront payment and as much as $7 billion of future milestones as Sanofi prepares for the eventual erosion of Dupixent exclusivity.
US medical groups fill CDC policy gap with independent 2026-27 respiratory vaccine recommendations
Major US medical groups issue independent flu, COVID-19 and RSV vaccine guidance as the traditional CDC recommendation process remains unsettled.
One leadership change, several major catalysts: What Vir Biotechnology must prove next
Vir Biotechnology’s finance leadership change comes as the biotechnology company manages more than $1 billion of financial resources, an important Astellas Pharma alliance and several potentially valuation-shaping clinical milestones.
Scribe Therapeutics IPO raises $128.7m as CRISPR biotech prepares to trade as SCTX
Scribe Therapeutics expanded the offering by 20% and priced shares at the top of its range, strengthening its balance sheet before crucial STX-1150 human data expected in 2027.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
AbbVie weighs $10.9bn Apogee deal to strengthen its next immunology growth cycle
AbbVie may pay $10.9 billion for Apogee Therapeutics before Phase 3. Read what the reported deal could mean for immunology growth and ABBV stock.
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.